MedTrace Logo

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

NCT06608433 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-02-11

No results posted yet for this study

Summary

This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.

Conditions

Interventions

DRUG

semaglutide

semaglutide/Rybelsus will be administered as a single oral dose

DRUG

Placebo

Placebo pills will be administered as a single oral dose

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2025-10-31
Completion
2025-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608433 on ClinicalTrials.gov